Welchol gains diabetes indication
Welchol (colesevelam HCl, from Daiichi Sankyo) has been approved by the FDA to improve glycemic control in adults with type 2 diabetes in combination with metformin, sulfonylureas, or insulin, either alone or in combination with other anti-diabetic agents. Clinical studies demonstrated that the addition of Welchol achieved significant reductions in hemoglobin A1c levels in patients not controlled by metformin, sulfonylurea or insulin alone. Welchol, a bile acid sequestrant, is already indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in patients with primary hypercholesterolemia as monotherapy or in combination with a statin.
For more information call (877) 437-7763 or visit www.Welchol.com.